Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by I. S. Nijhof
Daratumumab-Mediated Lysis of Primary Multiple Myeloma Cells Is Enhanced in Combination With the Human Anti-Kir Antibody IPH2102 and Lenalidomide
Haematologica
Hematology
Related publications
Disseminated Cryptococcosis in a Patient With Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone
Internal Medicine
Internal Medicine
Medicine
Daratumumab in Combination With Urelumab to Potentiate Anti-Myeloma Activity in Lymphocyte-Deficient Mice Reconstituted With Human NK Cells
OncoImmunology
Oncology
Allergy
Immunology
The Therapeutic Human CD38 Antibody Daratumumab Improves the Anti-Myeloma Effect of Newly Emerging Multi-Drug Therapies
Blood Cancer Journal
Oncology
Hematology
Clinical and Economic Study of Daratumumab in Combination Therapy for Previously Treated Patients With Multiple Myeloma
Medical Technologies. Assessment and Choice (Медицинские технологии. Оценка и выбор)
Daratumumab, Lenalidomide, and Dexamethasone (Drd) vs Lenalidomide and Dexamethasone (Rd) in Relapsed or Refractory Multiple Myeloma (Rrmm): Efficacy and Safety Update (Pollux)
Hematological Oncology
Medicine
Cancer Research
Oncology
Hematology
Cost-Effectiveness Analysis of Daratumumab, Lenalidomide, and Dexamethasone (DRD) and Daratumumab, Bortezomib, and Dexamethasone (DVD) Versus Standard of Care in Relapsed or Refractory Multiple Myeloma (RRMM)
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Daratumumab in Untreated Newly Diagnosed Multiple Myeloma
Therapeutic Advances in Hematology
Hematology
Low-Dose Lenalidomide and Dexamethasone Combination Treatment in Elderly Patients With Relapsed and Refractory Multiple Myeloma
Hematology
Hematology
Lenalidomide Induced Stroke in Multiple Myeloma
Clinical Practice
Medicine
Pharmacology
